Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the results of a trial (NCT02807558) investigating the combined treatment of the selective RARa agonist SY-1425, and azacitidine (aza) in RARA-positive, newly-diagnosed, acute myeloid leukemia (AML) patients. The trial was conducted following the identification of preclinical synergistic activity of combined SY-1425 and aza. It was found that RARA+ patients showed an overall response rate of 67%, with complete remission in 61%. The demonstrated clinical benefit of SY-2425 plus aza in RARA+ AML warrants further research. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.